Source comparison
MK-677 for Sleep Quality: Research Protocol Comparison
Before selecting a research protocol, understanding how dose, timing, and subject population affect outcomes is essential. The table below compares three published clinical trials that measured sleep architecture changes with MK-677 administration. Healthy you
This comparison does not assign a generated winner or score.
- Before selecting a research protocol, understanding how dose, timing, and subject population affect outcomes is essential. The table below compares three published clinical trials that measured sleep architecture changes with MK-677 administration.
- Healthy young men (ages 18–30)
- 25mg daily for 7 days
- 50% increase in REM duration; 20% increase in REM frequency vs baseline
- No change in total sleep time; subjective sleep quality scores unchanged
- MK-677 modulates sleep architecture without increasing sleep duration—depth over length
- Elderly adults (ages 64–81)
- 25mg daily for 8 weeks
- 75-minute increase in stage 4 sleep per night; significant improvement in sleep efficiency (ratio of time asleep to time in bed)
- IGF-1 levels increased 55% from baseline; fasting glucose elevated 8–12 mg/dL in 40% of subjects
- Sleep benefits pronounced in older adults with age-related GH decline; glucose monitoring required
- GH-deficient adults (verified via stimulation testing)
- 12.5mg daily titrated to 25mg over 4 weeks; maintained 12 months
- Normalized sleep architecture within 12 weeks; REM and SWS durations matched age-adjusted healthy controls
- Bone density improved; lean mass increased; water retention reported in 60% during first 8 weeks
- Most consistent sleep benefits in true GH deficiency; peripheral edema common but transient